I-Cocktail ye-Biologic Drug Drug for Prevention of the Common Hospital Infection

Unyango lwe-antibiotics ludla ngokuphumelela kwiimeko zokuqala ze-CDI. Nangona kunjalo, i-20% -40% yezigulane ziya kubandezeleka ngokuphindaphindiweyo, kwaye ithuba leepisodes ezongezelelweyo kwezi gulane lidlula i-40%. Iindlela ezikhoyo ngoku zokuthintela i-CDI ziphazanyiswa ziindleko eziphezulu, unikezelo olungeyomfuneko (kwiimeko ezininzi ezifuna ulawulo lwe-IV lwezilwa-buhlungu zesintu okanye i-bowel prep okanye i-enema yofakelo lwe-fecal microbiota).

I-Lumen Bioscience, inkampani ye-biopharmaceutical yenqanaba leklinikhi ephuhlisa amayeza ebhayoloji kwizifo ezixhaphake kakhulu, namhlanje ipapashe uphando oluchaza i-LMN-201, i-cocktail yophando yophando enikezelwe ngomlomo ukuthintela usulelo lwe-C. difficile (CDI). I-LMN-201 idibanisa iiprotheyini ezine zonyango-zenziwe kwaye zihanjiswe kwi-microorganism enokutyiwa i-spirulina-esebenza ngokubambisana ukuthomalalisa zombini i-C. difficile bacterium kunye ne-toxin ebangela ukuxhatshazwa kwayo.             

Iphepha elitsha, "Ukusebenzisa i-antibody synergy ukwenza injineli ephezulu ye-biologic cocktail ngokuchasene ne-C. difficile," ifakwe kwi-preprint server ye-bioRxiv elindele ukuphononongwa koontanga. Ichaza idatha ye-in vitro kunye ne-vivo ebonisa ukuba i-LMN-201 iyasebenza kakhulu ekuthinteleni i-CDI kwiimodeli ezimbini ezizimeleyo ze-CDI. Uphando lwenziwe ngoosonzululwazi be-Lumen kunye nabaphandi abakhokelayo kwibala le-CDI kwiilebhu zophando ezizimeleyo ezixhaswa ngokuyinxenye yinkxaso-mali evela kumaZiko eSizwe e-NIH ye-Allergy kunye neZifo ezosulelayo.

Eli phepha likwanika ingxelo ngenkqubela phambili ebalulekileyo kwisayensi yophuhliso lwe-cocktail ye-antibody enokuvumela amachiza e-antibody anamandla ngakumbi kwixesha elizayo. Umsebenzi ubonisa indlela yokusebenzisa uhlalutyo lobungakanani be-antibody synergy ukukhokela uphuhliso kunokonyusa amandla onyango lwe-cocktail ngamawakawaka. Lo mba wophando uneempembelelo ezicacileyo kwiithagethi zezifo ezininzi ngaphaya kwe-C. difficile, kubandakanywa neenkqubo zophuhliso lwe-Lumen zangaphambi kwekliniki kwisifo sokukrala kwamathumbu kunye nesifo se-cardiometabolic.

"I-LMN-201 iseka i-paradigm entsha ye-cocktails ekhuselekileyo nenamandla kakhulu ye-biologic kwiithagethi zesifo ngaphakathi kwephecana le-GI," kusho uJim Roberts, umseki weLumen kunye neGosa eliyiNtloko lezeNzululwazi. "Le ndlela ineziphumo ezithe kratya zokunyanga ezinye iziphazamiso ze-GI-centric ezineetiologies ezintsonkothileyo ezifana nesifo sikaCrohn, isifo sokuqaqamba kwamathumbu, izifo zemetabolism, kunye nesifo se-celiac, apho amandla afanayo kunye nemiceli mngeni ye-scalability ithintele uphuhliso lonyango lweprotheyini ehanjiswa ngomlomo."

Inkampani ikwabhengeze ukugqitywa kweQela loku-1 leSigaba soku-1 solingo lwezonyango lwe-pharmacokinetic lwe-LMN-201. Injongo ephambili kukuvavanya i-kinetics yokuchithwa kwee-capsules ze-enteric ezenzelwe ukukhulula iiprotheni zonyango ze-LMN-201 okanye ngaphambi kwe-ileum yokugcina, apho i-C. difficile isungulwa kwizigulane ezininzi. Ulingo ludibene nesiphelo salo esiphambili kwiQela le-1, elibonisa ukuba ii-capsules zinokuzisa ngempumelelo i-LMN-201 apho ifuneka khona. Emva kokugqitywa kweQela le-2 eliqinisekisayo lokufunda ekuqaleni konyaka ozayo, uhlalutyo olupheleleyo luya kugqitywa kwaye lupapashwe kwijenali ephononongwe ngontanga.